GDPR Compliance

We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

CVS Investors Have Opportunity to Lead CVS Health Corporation Securities Fraud Lawsuit

24newsclick staff ~ 9/10/2024
LOS ANGELES , Sept. 3 , 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ( `` GPM '' ) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CVS Health Corporation ( `` CVS '' or the `` Company '' ) (

LOS ANGELES, Sept. 3, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS).

Class Period: May 3, 2023April 30, 2024

Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP

Lead Plaintiff Deadline: September 10, 2024

If you wish to serve as lead plaintiff of the CVS lawsuit, you can submit your contact information at www.glancylaw.com/cases/CVS-Health-Corporation-1/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) the forecasts CVS used to determine plan premiums were ineffective at accounting for medical cost trends and health care utilization patterns; (2) as a result, CVS was likely to incur significant expenses to cover cost increases that were not accounted for in the Company's forecasts and thus not covered by plan premiums; (3) accordingly, CVS had overstated the profitability of its Health Care Benefits segment; (4) contrary to Defendants' assurances, the revenues generated from the Company's other primary segments were insufficient to offset the negative financial impact of the increasing expenditures within the Health Care Benefits segment; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224[email protected]www.glancylaw.com

SOURCE Glancy Prongay & Murray LLP Originally published at https://www.prnewswire.com/news-releases/cvs-investors-have-opportunity-to-lead-cvs-health-corporation-securities-fraud-lawsuit-302237035.html Images courtesy of https://pixabay.com

Photo by MART PRODUCTION via Pexels

More from Medicine